GB902658A — 6-substituted (or unsubstituted) 2-alkyl-3-allylthiomethyl-7-sulphamyl-3,4-dihydrobenzothiadiazine dioxides and process for preparation
Assigned to Pfizer Inc · Expires 1962-08-09 · 64y expired
What this patent protects
The invention comprises benzothiadiazine compounds of the formula <FORM:0902658/IV (b)/1> and salts thereof with pharmaceutically acceptable bases, e.g. Na, K, Ca and Mg, wherein A is hydrogen, Cl, Br, CF3 or a C1-3 alkyl or alkoxy group, e.g. CH3, and R is a lower alkyl gr…
USPTO Abstract
The invention comprises benzothiadiazine compounds of the formula <FORM:0902658/IV (b)/1> and salts thereof with pharmaceutically acceptable bases, e.g. Na, K, Ca and Mg, wherein A is hydrogen, Cl, Br, CF3 or a C1-3 alkyl or alkoxy group, e.g. CH3, and R is a lower alkyl group of 1-6 carbon atoms, and their preparation by reacting a disulphonamide of the formula <FORM:0902658/IV (b)/2> with an aldehyde of the formula Y.CH2.CHO wherein Y is an allyl mercapto group CH2 = CH-CH2.S-, or a halogen atom or an alkyl- or aryl-sulphonyloxy group and, when required, converting Y to an allyl mercapto group by condensing with allyl mercaptan. Pharmaceutical preparations, having diuretic activity, comprise the above compounds alone or with pharmaceutical carriers in a form suitable for oral administration such as tablets, capsules, trochees, lozenges or solutions, or in a form suitable for parenteral administration, for example in isotonic saline or glucose solution.
Drugs covered by this patent
- Zetia (EZETIMIBE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.